Clinical trials: in Peru
Osteoarthritis
A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee
The objective of this 2-year study is to evaluate the safety, tolerability and disease modifying efficacy of SD 6010, an inhibitor of inducible nitric oxide synthase (iNOS), in overweight and obese subjects with knee…
- Trial name
- ITIC (NCT00565812)
- Testing
- SD-6010
- Where
- 183 sites in United States, Argentina and 12 more
- Volunteers
- 1,457 people
- Sponsor
- Pfizer
Nutritional Status, Malnutrition
Screening Day Latin America
This is a survey which will be performed on a specific day (the "Screening Day") in Latin American ICUs. In eligible patients who receive enteral or parenteral nutrition a retrospective calculation of the "caloric deficit" will…
- Conditions
- Nutritional Status, Malnutrition, Caloric Deficit
- Trial name
- NCT02583880
- Where
- 121 sites in Argentina, Brazil and 6 more
- Volunteers
- 1,162 people
- Sponsor
- Fresenius Kabi
Acute Coronary Syndrome
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Primary Objective: To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable…
- Trial name
- ELIXA (NCT01147250)
- Testing
- Lixisenatide (AVE0010)
- Where
- 829 sites in United States, Argentina and 47 more
- Volunteers
- 6,068 people
- Sponsor
- Sanofi
Healthy
Safety of Lactobacillus Reuteri in Healthy Volunteers
This is a phase one study to assess the safety of daily dosing of Lactobacillus reuteri in healthy adults in Peru. It is conducted as a preliminary study in support of a clinical trial to assess safety and efficacy of…
- Trial name
- NCT00774163
- Testing
- Lactobacillus reuteri
- Where
- Peru
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tulane University School of Medicine
Pulmonary Disease, Chronic Obstructive
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This study will assess the safety and efficacy of 5 doses GW642444 in subjects with Chonic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT00606684
- Testing
- GW642444 6.25, GW642444 3mcg, GW642444 12.5mcg
- Where
- 99 sites in United States, Argentina and 12 more
- Volunteers
- 602 people
- Sponsor
- GlaxoSmithKline
Asthma
A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma
This study is to assess the safety of an investigational drug in children 4 to 11 years of age who have asthma. The subjects will attend 7 clinic visits, of which up to 3 will be in the morning, and have lung function tests…
- Trial name
- NCT00441441
- Testing
- fluticasone propionate, fluticasone propionate/salmeterol
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 351 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma
- Trial name
- NCT00600171
- Testing
- GW642444M
- Where
- 89 sites in United States, Argentina and 14 more
- Volunteers
- 614 people
- Sponsor
- GlaxoSmithKline
Asthma
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents
The purpose of the study is to evaluate the safety of Symbicort compared to inhaled corticosteroid alone during 6 months in adult and adolescent patients with asthma
- Trial name
- NCT01444430
- Testing
- Symbicort pMDI, budesonide pMDI
- Where
- 340 sites in United States, Argentina and 24 more
- Volunteers
- 12,460 people
- Sponsor
- AstraZeneca
Fallopian Tube Cancer, Ovarian Cancer
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01204749
- Testing
- AMG 386, Paclitaxel
- Where
- 225 sites in United States, Australia and 30 more
- Volunteers
- 919 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active…
- Trial name
- BLISS-52 (NCT00424476)
- Testing
- Belimumab 1 mg/kg, Belimumab 10 mg/kg
- Where
- 92 sites in Argentina, Australia and 11 more
- Volunteers
- 865 people
- Sponsor
- Human Genome Sciences Inc.
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with…
- Trial name
- HELOISE (NCT01450696)
- Testing
- Capecitabine, Cisplatin, Herceptin
- Where
- 117 sites in United States, Australia and 23 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to pioglitazone with or without metformin, over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-P (NCT00763815)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Pioglitazone
- Where
- 150 sites in United States, Austria and 11 more
- Volunteers
- 484 people
- Sponsor
- Sanofi
Chronic Heart Failure
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure…
- Trial name
- ATMOSPHERE (NCT00853658)
- Testing
- Enalapril, Aliskiren
- Where
- 806 sites in United States, Argentina and 42 more
- Volunteers
- 7,064 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease, COPD
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
The aim of the study is to compare the effect of roflumilast and placebo on the lung function in patients with COPD.
- Trial name
- NCT00062582
- Testing
- Roflumilast
- Where
- 37 sites in United States, Argentina and 4 more
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Hypertension
A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
The purpose of this study is to collect the long-term (12 months) safety data on aliskiren 300 mg when taken in combination with HCTZ 25 mg.
- Trial name
- NCT00171405
- Testing
- aliskiren
- Where
- 10 sites in United States, Belgium and 8 more
- Volunteers
- 250 people
- Sponsor
- Novartis
Asthma
Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
The primary objective of the study is to evaluate the effect of multiple-dose subcutaneous administrations of MEDI-563 on adults with uncontrolled asthma.
- Trial name
- NCT01238861
- Testing
- Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg
- Where
- 74 sites in United States, Argentina and 8 more
- Volunteers
- 964 people
- Sponsor
- MedImmune LLC
Renal Cell Carcinoma
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
This study assessed the efficacy and safety of first-line RAD001 followed by second-line sunitinib versus the opposite sequence: first-line sunitinib followed by second-line RAD001 for the treatment of patients with MRCC.
- Trial name
- RECORD-3 (NCT00903175)
- Testing
- everolimus, sunitinib
- Where
- 84 sites in United States, Argentina and 17 more
- Volunteers
- 471 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus Type 2
A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.
This 4 arm study will assess the efficacy, safety and tolerability of taspoglutide compared to sitagliptin and placebo in patients with type 2 diabetes mellitus inadequately controlled with metformin.
- Trial name
- NCT00754988
- Testing
- Metformin, Sitagliptin, Taspoglutide
- Where
- 148 sites in United States, Argentina and 21 more
- Volunteers
- 666 people
- Sponsor
- Hoffmann-La Roche
Soft Tissue Infections
A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
This 3 arm study will compare the efficacy and safety of beta-lactam with that of 'standard care' in patients with complicated skin and skin structure infections requiring hospitalization.
- Trial name
- NCT00303589
- Testing
- Standard care, beta-lactam
- Where
- 62 sites in United States, Argentina and 9 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
This is a Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study enrolling patients with active rheumatoid arthritis (RA).
- Trial name
- NCT01225393
- Testing
- MLTA3698A, adalimumab, leflunomide
- Where
- 67 sites in United States, Bulgaria and 8 more
- Volunteers
- 211 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.